Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: stockdoc77 who wrote (38489)	1/6/2017 11:47:55 PM
From: drtom1234	4 Recommendations Read Replies (2) of 63291

You don't think companies interested in 132 haven't already had some "feeling out" talks with Venbio? I suspect it would take very little time to negotiate European and Asian rights to 132 with a board and CEO who actually know what they're doing, and are interested in making a deal that would be good for both companies, not "winning" a deal. Another possibility; if the company does get AA, I would imagine they could get a line of credit to help them get through any time it took to make a deal with BP. My point is, the situation is not as dire as your post tried to make it. Venbio is clearly the better management option here, regardless of the circumstance.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next